Search

Your search keyword '"Négrier S"' showing total 288 results

Search Constraints

Start Over You searched for: Author "Négrier S" Remove constraint Author: "Négrier S"
288 results on '"Négrier S"'

Search Results

3. HSD117 Healthcare Resources Utilization (HCRU) and Exploration of the Patient Journey through Claims Database: An Application on Advanced Renal Cell Carcinoma (ARCC) Patients in France

4. Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

6. EE171 Hospital Costs of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients Undergoing Radical Surgery: A French Real-World Retrospective Study Based on the National Hospitalization Database (PMSI)

7. P37 Impact of Method for Modelling Distant Recurrence (DR) on Cost-Effectiveness (CE) of Nivolumab (NIVO) as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) Patients With High Risk of Recurrence in France

21. O12 - Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial

22. 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial

23. 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

25. 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial

28. 1480P Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (NIVO) within the NIVOREN trial

29. 1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era

32. First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts’ Prescribing Practices and Systematic Literature Review

38. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

40. Mise en place de fiducials surrénaliens sous contrôle écho-endoscopique (EE) et radioscopique avant radiothérapie stéréotaxique (RTS): intérêt, faisabilité et sécurité à propos de 6 cas consécutifs (Première série rapportée)

41. Kidney

42. 1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

46. 909PD - NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)

47. 908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Catalog

Books, media, physical & digital resources